Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Offer Update

15 Aug 2005 07:01

Torex Retail PLC15 August 2005 Torex Retail Plc15 August 2005 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN TOREX RETAIL PLC ___________________________________________________________________________ RECOMMENDED OFFER FOR ANKER PLC Offer Unconditional as to Acceptances As at 3.00 p.m. on 12 August 2005, valid acceptances had been received inrespect of 40,810,140 Anker Shares (representing approximately 98.14 per cent ofAnker's issued share capital). Accordingly, the Board of Torex Retail Plc("Torex Retail") announces that the offer (the "Offer") made by UBS InvestmentBank on behalf of Torex Retail for Anker Plc ("Anker") has been declaredunconditional as to acceptances. Prior to the posting of the Offer Document, Torex Retail had receivedirrevocable undertakings or letters of intent from the Anker Directors andcertain other Anker Shareholders to accept or procure the acceptance of theOffer in respect of, in aggregate, 31,347,988 Anker Shares, representingapproximately 75.4 per cent. of the existing issued ordinary share capital ofAnker. Included in the valid acceptances of the Offer set out above areacceptances in respect of 31,347,988 Anker Shares, representing approximately75.4 per cent. of the existing issued ordinary share capital of Anker, receivedpursuant to such irrevocable undertakings and letter of intent. The Offer remains conditional upon the admission to trading on AIM of the NewTorex Retail Shares issued as consideration under the Offer becoming effective. Therefore, following the allocations made pursuant to the Mix and Matchfacility, application has been made for the admission of 55,297,740 New TorexRetail Shares to trading on AIM and it is expected that these New Torex RetailShares will be admitted to trading on AIM and that dealings in those shares willcommence on 18 August 2005, when it is also expected that the Offer will becomewholly unconditional. The board of Torex Retail announces that the Mix and Match Facility has now beenclosed with effect from 3.00 p.m. on 12 August 2005. Those Anker Shareholdersthat elected to receive additional cash under the Mix and Match Facility willreceive in total 94.2 pence in cash and 1.193 New Torex Retail Shares for everyAnker share held. Elections to receive additional New Torex Retail Shares underthe Mix and Match Facility will be received in full. The Offer will remain open for acceptance until further notice, although the Mixand Match Facility is no longer available. For Anker Shares held in certificated form, Forms of Acceptance should becompleted, signed and returned in accordance with instructions set out in theOffer Document and in the Form of Acceptance, so as to be received as soon aspossible. For Anker Shares held in uncertificated form, an ElectronicAcceptance should be made in accordance with instructions set out in the OfferDocument so that the TTE Instruction settles as soon as possible. Save as disclosed in this announcement, neither Torex Retail nor any personsdeemed to be acting in concert with it for the purposes of the Offer owned anyAnker Shares (or rights over such shares) on 29 June 2005 (being the lastdealing day prior to the commencement of the Offer period) nor has Torex Retailnor any person deemed to be acting in concert with it for the purposes of theOffer acquired or agreed to acquire any Anker Shares (or rights over suchshares) during the Offer period other than by way of acceptances of the Offer. The Offer will remain open until further notice. At least 14 days' notice willbe given before the Offer is closed. Terms defined in the formal offer document dated 22 July 2005 (the "OfferDocument") shall, unless the context requires otherwise, have the same meaningsin this announcement. EnquiriesTorex Retail Telephone: 01993 230 030Richard Thompson / Nigel Horn UBS Investment Bank Telephone: 020 7567 8000Ben Robertson/Jackie Lee This announcement is issued by UBS Investment Bank which is authorised andregulated in the United Kingdom by the Financial Services Authority. UBSInvestment Bank is acting exclusively for Torex Retail and is acting for no oneelse in connection with the Offer and will not be responsible to anyone otherthan Torex Retail for providing the protections afforded to customers of UBSInvestment Bank nor for providing advice in relation to the Offer. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Nov 20249:32 amRNSForm 8.3 - Tissue Regenix Group Plc
12th Nov 20244:05 pmRNSForm 8 (OPD) (Tissue Regenix Group Plc)
12th Nov 20248:46 amRNSForm 8.5 (EPT/NON-RI)
11th Nov 20249:17 amRNSForm 8.5 (EPT/NON-RI)
7th Nov 20249:59 amRNSForm 8.5 (EPT/NON-RI) - Tissue Regenix Group PLC
6th Nov 20241:37 pmRNSForm 8.3 - Tissue Regenix Group PLC
6th Nov 20248:52 amRNSForm 8.5 (EPT/NON-RI)
5th Nov 20242:24 pmRNSForm 8.3 - Tissue Regenix Group PLC
5th Nov 202411:32 amRNSForm 8.5 (EPT/NON-RI)
4th Nov 20244:36 pmRNSResponse to media speculation
10th Sep 20247:00 amRNSInterim results for the six months ended 30 June
18th Jul 20243:52 pmRNSGrant of share options
16th Jul 20247:00 amRNSHalf-Year Trading Update
3rd Jul 20241:16 pmRNSHolding(s) in Company
24th Jun 20244:12 pmRNSHolding(s) in Company
18th Jun 20245:15 pmRNSExercise of Options, Director Dealing and TVR
14th Jun 20247:00 amRNSBuilding purchase
25th Apr 20242:27 pmRNSResult of AGM
10th Apr 20247:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth
5th Apr 20243:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSFinal results for the year ended 31 December 2023
1st Mar 20247:00 amRNSNotice of Results
6th Feb 20247:00 amRNSFirst EU shipment & new distributor agreements
29th Jan 20243:02 pmRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading update for 2023
23rd Jan 20245:24 pmRNS2023 LTIP Grant
22nd Nov 20234:36 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSHPRA approval & distribution agreement in Spain
18th Sep 202310:40 amEQSHardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
15th Sep 20234:30 pmRNSDirector/PDMR Shareholding
5th Sep 20237:01 amRNSNew sports medicine product launch
5th Sep 20237:00 amRNSInterim results
31st Aug 20231:45 pmRNSExercise of Options and Total Voting Rights
21st Aug 20237:00 amRNSNotice of interim results
17th Jul 20237:00 amRNSHalf-Year Trading Update
10th Jul 20237:00 amRNSDistribution agreement for OrthoPure® XT in the UK
25th May 20237:00 amRNSDistribution agreement with Australian Allografts
9th May 202312:00 pmRNSHolding(s) in Company
27th Apr 202312:35 pmRNSResult of AGM, Share Reorganisation &TVR
18th Apr 20237:00 amRNSProposed Share Reorganisation Timetable
5th Apr 20232:55 pmEQSHardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
5th Apr 20237:00 amRNSCEO and CFO Share Purchases
30th Mar 20237:00 amRNSHolding(s) in Company
21st Mar 20237:00 amRNSFinal results for the year ended 31 December 2022
6th Mar 20237:00 amRNSNotice of results and Investor presentation
31st Jan 20237:01 amRNSTrading update for 2022
31st Jan 20237:00 amRNSChange of Adviser
18th Jan 202310:06 amRNSHolding(s) in Company
18th Jan 20237:00 amRNSChinese distribution agreement for OrthoPure® XT
7th Dec 20227:00 amRNSProduct launch in dCELL® division

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.